CDA S.A. (WSE:CDA)

Inozyme Pharma Cash Flow Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	26.77	26.44	24.85	19.53	19.04	16.35
Depreciation & Amortization	0.6	0.63	0.47	0.49	1.1	1.11
Loss (Gain) From Sale of Assets	-	-	-0.06	-	-0.07	-0.02
Change in Accounts Receivable	-0.6	-0.22	-0.8	-0.52	0.16	-0.56
Change in Inventory	-1.25	-0.8	-0.95	-0.39	-0.19	-
Change in Other Net Operating Assets	-3.75	1.17	-2.51	-3.5	-1.77	2.77
Operating Cash Flow	21.78	27.22	20.99	15.62	18.27	19.66
Operating Cash Flow Growth	-15.80%	29.64%	34.39%	-14.51%	-7.04%	105.45%
Capital Expenditures	-0.65	-0.72	-1.05	-0.42	-0.38	-0.21
Sale of Property, Plant & Equipment	-	-	0.14	-	0.07	0.02
Investing Cash Flow	-0.65	-0.72	-0.91	-0.42	-0.31	-0.19
Long-Term Debt Repaid	-	-0.13	-0.08	-	-	-
Net Debt Issued (Repaid)	-0.14	-0.13	-0.08	-	-	-
Issuance of Common Stock	-	-	0.18	0.18	0.26	0.15
Common Dividends Paid	-24.73	-24.73	-15.94	-18.96	-18.38	-7.13
Other Financing Activities	-0.03	-0.24	0.25	0.01	0.03	-0
Financing Cash Flow	-24.89	-25.1	-15.59	-18.77	-18.09	-6.98
Net Cash Flow	-3.77	1.4	4.49	-3.57	-0.13	12.48
Free Cash Flow	21.13	26.5	19.94	15.21	17.9	19.45
Free Cash Flow Growth	-14.88%	32.89%	31.14%	-15.02%	-7.98%	137.41%
Free Cash Flow Margin	19.93%	25.51%	23.52%	21.26%	26.08%	32.13%
Free Cash Flow Per Share	2.05	2.57	1.94	1.48	1.75	1.91
Levered Free Cash Flow	18.82	24.4	14.51	14.87	15.17	16.68
Unlevered Free Cash Flow	18.84	24.43	14.58	15.35	15.17	16.68
Change in Working Capital	-5.6	0.15	-4.26	-4.4	-1.8	2.22

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.